140 related articles for article (PubMed ID: 1662891)
1. In vitro activity of temafloxacin against pathogens causing sexually transmitted diseases.
Segreti J
Am J Med; 1991 Dec; 91(6A):24S-26S. PubMed ID: 1662891
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of lomefloxacin against Chlamydia trachomatis, Neisseria gonorrhoeae, Haemophilus ducreyi, Mycoplasma hominis, and Ureaplasma urealyticum.
Hoban D; DeGagne P; Witwicki E
Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):83S-86S. PubMed ID: 2507222
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens.
Lefèvre JC; Bauriaud R; Gaubert E; Escaffre MC; Lareng MB
Chemotherapy; 1992; 38(5):303-7. PubMed ID: 1337506
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of the two new 4-quinolones A56619 and A56620 against Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum and Gardnerella vaginalis.
Tjiam KH; Wagenvoort JH; van Klingeren B; Piot P; Stolz E; Michel MF
Eur J Clin Microbiol; 1986 Oct; 5(5):498-501. PubMed ID: 3096726
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of temafloxacin against gram-negative bacteria: an overview.
Hardy DJ
Am J Med; 1991 Dec; 91(6A):19S-23S. PubMed ID: 1662890
[TBL] [Abstract][Full Text] [Related]
6. Comparative in-vitro activity of sparfloxacin against genital pathogens.
Perea EJ; Aznar J; Garcia-Iglesias MC; Pascual A
J Antimicrob Chemother; 1996 May; 37 Suppl A():19-25. PubMed ID: 8737122
[TBL] [Abstract][Full Text] [Related]
7. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.
Kenny GE; Cartwright FD
Antimicrob Agents Chemother; 1993 Aug; 37(8):1726-7. PubMed ID: 8215294
[TBL] [Abstract][Full Text] [Related]
8. The role of fluoroquinolones in sexually transmitted diseases.
Tartaglione TA; Hooton TM
Pharmacotherapy; 1993; 13(3):189-201. PubMed ID: 8321733
[TBL] [Abstract][Full Text] [Related]
9. In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.
Furneri PM; Bisignano G; Cerniglia G; Nicoletti G; Cesana M; Tempera G
Antimicrob Agents Chemother; 1994 Nov; 38(11):2651-4. PubMed ID: 7872762
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of tosufloxacin (A-61827; T-3262) against selected genital pathogens.
Segreti J; Hirsch DJ; Harris AA; Kapell KS; Orbach H; Kessler HA
Antimicrob Agents Chemother; 1990 Jun; 34(6):971-3. PubMed ID: 2118330
[TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolones for the treatment of nongonococcal urethritis/cervicitis.
Segreti J
Am J Med; 1991 Dec; 91(6A):150S-152S. PubMed ID: 1662887
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and treatment of Chlamydia trachomatis, Ureaplasma urealyticum, and Mycoplasma hominis in patients with non-gonococcal urethritis.
Kilic D; Basar MM; Kaygusuz S; Yilmaz E; Basar H; Batislam E
Jpn J Infect Dis; 2004 Feb; 57(1):17-20. PubMed ID: 14985631
[TBL] [Abstract][Full Text] [Related]
13. In vitro antimicrobial activity of rosoxacin against Neisseria gonorrhoeae, Chlamydia trachomatis, and Ureaplasma urealyticum.
Dobson RA; O'Connor JR; Poulin SA; Kundsin RB; Smith TF; Came PE
Antimicrob Agents Chemother; 1980 Nov; 18(5):738-40. PubMed ID: 6778385
[TBL] [Abstract][Full Text] [Related]
14. Activity of temafloxacin and other fluoroquinolones against typical and atypical community-acquired respiratory tract pathogens.
Hardy DJ
Am J Med; 1991 Dec; 91(6A):12S-14S. PubMed ID: 1662881
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of azithromycin against Chlamydia trachomatis, Ureaplasma urealyticum and Mycoplasma hominis in comparison with erythromycin, roxithromycin and minocycline.
Rumpianesi F; Morandotti G; Sperning R; Satta G; Cevenini R
J Chemother; 1993 Jun; 5(3):155-8. PubMed ID: 8396626
[TBL] [Abstract][Full Text] [Related]
16. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).
Kenny GE; Cartwright FD
Antimicrob Agents Chemother; 1996 Apr; 40(4):1048-9. PubMed ID: 8849228
[TBL] [Abstract][Full Text] [Related]
17. [Clinical effect of NY-198 (lomefloxacin) for sexually transmitted disease--bacteriological effect of U. urealyticum].
Kawamura N; Nishizawa K; Kawashima T; Koinuma A; Ohhara K
Kansenshogaku Zasshi; 1990 Jan; 64(1):1-11. PubMed ID: 2335746
[TBL] [Abstract][Full Text] [Related]
18. The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.
Ridgway GL; Salman H; Robbins MJ; Dencer C; Felmingham D
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():31-4. PubMed ID: 9484871
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of lomefloxacin, tetracycline, penicillin, spectinomycin, and ceftriaxone against Neisseria gonorrhoeae and Chlamydia trachomatis.
Talbot H; Romanowski B
Antimicrob Agents Chemother; 1989 Dec; 33(12):2049-51. PubMed ID: 2533473
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.
Waites KB; Cassell GH; Canupp KC; Fernandes PB
Antimicrob Agents Chemother; 1988 Oct; 32(10):1500-2. PubMed ID: 2973283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
